Table 2 Clinical Characteristics and outcome of the HCC patients with EHMP

Age, years^{a, ‡}

64.3 ± 2.6

62.5 ± 2.8

63.3 ± 4.2

63.1 ± 1.8

0.936

Male sex^b

4 (57.1)

14 (82.4)

7 (77.8)

25 (75.8)

0.487

Smoking, >10 pack-years^b

3 (42.9)

6 (35.3)

3 (37.5)

12 (37.5)

1.000

Etiology of liver disease^b

0.471

 HBsAg (+)

5 (71.4)

6 (35.3)

5 (55.6)

16 (48.5)

 Anti-HCV (+)

1 (14.3)

1(5.9)

0 (0.0)

2 (6.1)

 Alcohol

0 (0.0)

5(29.4)

1 (11.1)

6 (18.2)

 Other

1 (14.3)

5(29.4)

3 (33.3)

9 (27.3)

CTP score^b

0.212

 A

6 (85.7)

17 (100.0)

9 (100.0)

32 (97.0)

 B

1 (14.3)

0 (0.0)

0 (0.0)

1 (3.0)

pTNM stage of HCC^b

0.191

 I

2 (28.6)

12 (70.6)

5 (55.6)

19 (57.6)

 II

4 (57.1)

3 (17.6)

4 (44.4)

11 (33.3)

 III or IV

1 (14.3)

2 (11.8)

0 (0.0)

3 (9.1)

AFP (ng/mL)^b

0.470

 <20

5 (71.4)

11 (68.8)

4 (50.0)

20 (64.5)

 20–200

0 (0.0)

2 (12.5)

3 (37.5)

5 (16.1)

 >200

2 (28.6)

3 (18.8)

1 (12.5)

6 (19.4)

Location of EHPM^b

 Esophagus

0 (0.0)

1 (5.9)

0 (0.0)

1 (3.0)

1.000

 Stomach

4 (57.1)

4 (23.5)

1 (11.1)

9 (27.3)

0.152

 Colorectal

1 (14.3)

6 (35.3)

3 (33.3)

10 (30.3)

0.697

 Pancreas

0 (0.0)

0 (0.0)

1 (11.1)

1 (3.0)

0.485

 Common bile duct

0 (0.0)

0 (0.0)

1 (11.1)

1 (3.0)

0.485

 Breast

2 (28.6)

2 (11.8)

0 (0.0)

4 (12.1)

0.222

 Thyroid

0 (0.0)

0 (0.0)

1 (11.1)

1 (3.0)

0.485

 Kidney

1 (14.3)

2 (11.8)

0 (0.0)

3 (9.1)

0.579

 Bladder

0 (0.0)

0 (0.0)

1 (11.1)

1 (3.0)

0.485

 Prostate

0 (0.0)

0 (0.0)

1 (11.1)

1 (3.0)

0.485

 Retroperitoneum

0 (0.0)

1 (5.9)

0 (0.0)

1 (3.0)

1.000

 Bone marrow

0 (0.0)

1 (5.9)

0 (0.0)

1 (3.0)

1.000

pTNM stage of EHPM

0.166

 0

0 (0.0)

1 (5.9)

0 (0.0)

1 (3.3)

 1

4 (80.0)

8 (47.1)

1 (12.5)

13 (43.3)

 2

1 (20.0)

4 (23.5)

1 (12.5)

6 (20.0)

 3

0 (0.0)

3 (17.6)

5 (62.5)

8 (26.7)

 4

0 (0.0)

1 (5.9)

1 (12.5)

2 (6.7)

Treatment of EHPM^b

1.000

 Operation

7 (100.0)

14 (82.4)

7 (77.8)

28 (84.8)

 Radiation or Chemotherapy

0 (0.0)

1 (5.9)

1 (11.1)

2 (6.1)

 Supportive care

0 (0.0)

2 (11.8)

1 (11.1)

3 (9.1)

Progression or recurrence of EHPM^b

0 (0.0)

6 (35.3)

3 (33.3)

9 (27.3)

0.221

Follow-up duration (months)^a

18.4 ± 5.9

35.9 ± 6.7

49.8 ± 12.5

36.0 ± 5.2

0.115

Overall median survival (months)

18.0

32.0

38.0

28.0

Recurrence of HCC^b

3 (42.9)

5 (29.4)

2 (22.2)

10 (30.3)

0.781

Death^b

2 (28.6)

7 (41.2)

2 (22.2)

11 (33.3)

0.628

Cause of death^b

0.697

 Liver-related

1 (50.0)

3 (42.9)

2 (100.0)

6 (100.0)

 Other

1 (50.0)

4 (57.1)

0 (0.0)

5 (100.0)